MX2018000459A - Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos. - Google Patents
Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos.Info
- Publication number
- MX2018000459A MX2018000459A MX2018000459A MX2018000459A MX2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A MX 2018000459 A MX2018000459 A MX 2018000459A
- Authority
- MX
- Mexico
- Prior art keywords
- nitrogen
- containing heterocyclic
- heterocyclic compound
- production method
- compound
- Prior art date
Links
- -1 nitrogen-containing heterocyclic compound Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención resuelve el problema de proporcionar un método para fabricar industrialmente un compuesto heterocíclico que contiene nitrógeno que tiene una actividad inhibidora de FLT3 excelente y es útil como un ingrediente farmacéutico activo de un agente farmacéutico. Se proporciona un método de fabricación que utiliza un compuesto representado por la fórmula general [14] (en la fórmula, R1 representa un grupo alquilo de C1-6 opcionalmente sustituido y R8 representa un grupo saliente o similar) o una sal de tal compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015141034A JP6412471B2 (ja) | 2015-07-15 | 2015-07-15 | 含窒素複素環化合物の製造方法およびその中間体 |
| PCT/JP2016/070758 WO2017010535A1 (ja) | 2015-07-15 | 2016-07-14 | 含窒素複素環化合物の製造方法およびその中間体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018000459A true MX2018000459A (es) | 2018-09-07 |
Family
ID=57758235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000459A MX2018000459A (es) | 2015-07-15 | 2016-07-14 | Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10435377B2 (es) |
| EP (1) | EP3323811B1 (es) |
| JP (1) | JP6412471B2 (es) |
| KR (1) | KR102032140B1 (es) |
| CN (1) | CN107848987B (es) |
| AU (1) | AU2016294197B2 (es) |
| BR (1) | BR112018000759A2 (es) |
| CA (1) | CA2992403C (es) |
| DK (1) | DK3323811T3 (es) |
| ES (1) | ES2729958T3 (es) |
| IL (1) | IL256809B (es) |
| MX (1) | MX2018000459A (es) |
| NZ (1) | NZ738953A (es) |
| PL (1) | PL3323811T3 (es) |
| RU (1) | RU2717830C2 (es) |
| SG (1) | SG11201800245QA (es) |
| TR (1) | TR201909774T4 (es) |
| TW (1) | TWI711605B (es) |
| WO (1) | WO2017010535A1 (es) |
| ZA (1) | ZA201800269B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202027749A (zh) | 2018-10-12 | 2020-08-01 | 日商富士軟片股份有限公司 | 急性骨髓性白血病用抗腫瘤劑 |
| JPWO2020090968A1 (ja) * | 2018-10-31 | 2021-09-16 | 富士フイルム株式会社 | 抗腫瘍剤を含む造粒物 |
| WO2020090969A1 (ja) * | 2018-10-31 | 2020-05-07 | 富士フイルム株式会社 | 抗腫瘍剤を含む医薬組成物の包装体 |
| TW202045174A (zh) | 2019-02-28 | 2020-12-16 | 日商富士軟片股份有限公司 | 組合醫藥 |
| AU2022426699A1 (en) | 2021-12-30 | 2024-07-11 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928839D0 (en) | 1989-12-21 | 1990-02-28 | Beecham Group Plc | Novel compounds |
| PT1438053E (pt) | 2001-10-17 | 2008-09-25 | Boehringer Ingelheim Int | Derivados de pirimidina, medicamento contendo estes compostos, sua utilização e processo para a sua preparação |
| CA2608367C (en) | 2005-06-08 | 2014-08-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20060281755A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| US8071768B2 (en) * | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| EP3173084B1 (en) | 2005-11-11 | 2019-10-23 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
| PL2001892T3 (pl) | 2006-03-17 | 2013-09-30 | Ambit Biosciences Corp | Imidazolotiazolowe związki do leczenia chorób proliferacyjnych |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| CA2713553A1 (en) | 2008-02-01 | 2009-08-06 | Akinion Pharmaceuticals Ab | Pyrazine derivatives and their use as protein kinase inhibitors |
| BR122012027456A2 (pt) | 2008-03-14 | 2015-07-14 | Allergan Inc | Composição farmacêutica compreendendo sorotipo de neurotoxina botulínica a |
| WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| ES2635713T3 (es) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| WO2012135801A1 (en) | 2011-04-01 | 2012-10-04 | University Of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| JP5978293B2 (ja) | 2011-05-04 | 2016-08-24 | フォーマ ティーエム， エルエルシー． | Ｎａｍｐｔを阻害するための新規な化合物および組成物 |
| JP2013157540A (ja) | 2012-01-31 | 2013-08-15 | Toshiba Corp | 半導体装置およびその製造方法 |
| HUE036582T2 (hu) * | 2012-04-17 | 2018-07-30 | Fujifilm Corp | Nitrogéntartalmú heterociklusos vegyület vagy annak sója |
| ES2738573T3 (es) * | 2013-10-16 | 2020-01-23 | Fujifilm Corp | Sal de compuesto heterocíclico que contiene nitrógeno o cristal del mismo, composición farmacéutica e inhibidor de FLT3 |
| KR20150056683A (ko) | 2013-11-15 | 2015-05-27 | (주) 제일피앤티 | 대전 방지 필름 및 이를 이용한 쉴드 백 |
| WO2016027904A1 (ja) | 2014-08-22 | 2016-02-25 | 富士フイルム株式会社 | Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用 |
-
2015
- 2015-07-15 JP JP2015141034A patent/JP6412471B2/ja active Active
-
2016
- 2016-07-14 KR KR1020187000990A patent/KR102032140B1/ko not_active Expired - Fee Related
- 2016-07-14 RU RU2018100967A patent/RU2717830C2/ru active
- 2016-07-14 PL PL16824515T patent/PL3323811T3/pl unknown
- 2016-07-14 TR TR2019/09774T patent/TR201909774T4/tr unknown
- 2016-07-14 SG SG11201800245QA patent/SG11201800245QA/en unknown
- 2016-07-14 ES ES16824515T patent/ES2729958T3/es active Active
- 2016-07-14 DK DK16824515.7T patent/DK3323811T3/da active
- 2016-07-14 MX MX2018000459A patent/MX2018000459A/es unknown
- 2016-07-14 NZ NZ738953A patent/NZ738953A/en not_active IP Right Cessation
- 2016-07-14 BR BR112018000759-5A patent/BR112018000759A2/pt active Search and Examination
- 2016-07-14 EP EP16824515.7A patent/EP3323811B1/en active Active
- 2016-07-14 AU AU2016294197A patent/AU2016294197B2/en not_active Ceased
- 2016-07-14 WO PCT/JP2016/070758 patent/WO2017010535A1/ja not_active Ceased
- 2016-07-14 CA CA2992403A patent/CA2992403C/en active Active
- 2016-07-14 CN CN201680041023.4A patent/CN107848987B/zh not_active Expired - Fee Related
- 2016-07-14 TW TW105122147A patent/TWI711605B/zh not_active IP Right Cessation
-
2018
- 2018-01-09 IL IL256809A patent/IL256809B/en active IP Right Grant
- 2018-01-10 US US15/867,122 patent/US10435377B2/en active Active
- 2018-01-15 ZA ZA2018/00269A patent/ZA201800269B/en unknown
-
2019
- 2019-02-11 US US16/272,263 patent/US10562862B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| MX2018007418A (es) | Compuestos de benzamida y sus usos como herbicidas. | |
| SG10201805628TA (en) | Deuterated heterocyclic compounds and their use as imaging agents | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12016502358B1 (en) | Novel pyrrolidine compound and application as melanocortin receptor agonist | |
| MX2018003554A (es) | Benzamidas sustituidas con isoxazolina y analogos como insecticidas. | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2018000459A (es) | Metodo para la fabricacion de compuestos heterociclicos que contienen nitrogeno y compuestos intermediarios de los mismos. | |
| PH12014501711A1 (en) | Benzyl sulfonamide derivatives useful as mogat-2 inhibitors | |
| MX2019012454A (es) | Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
| PH12019500839A1 (en) | Therapeutic compounds and methods of use thereof | |
| MX2018014813A (es) | Composiciones antibacterianas. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MX2019004293A (es) | Derivados de fenilamina sustituidos en la posicion 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatogenos no deseados. | |
| PH12016502568B1 (en) | Novel heterocyclic compound | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
| PH12017500435B1 (en) | A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof | |
| PH12015502060A1 (en) | Hydrochloride salts of an antibiotic compound | |
| TN2014000308A1 (en) | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors | |
| WO2016047967A3 (ko) | N-(5-아릴아미도-2-메틸페닐)-5-메틸이소옥사졸-4-카복스아미드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 fms 키나아제 저해제 |